Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
The latest available 13F covers holdings as of Jun 30, 2026 (Q2 2026) and was filed Aug 14, 2026. Quarter-end snapshot, not a live trade.
Disclosed 13F value
$38.9B
sum of reported positions
Reported positions
652
Changes vs prior quarter
791
244 new · 197 exited
Filings on record
9
Q2 2026, Q1 2026, Q4 2025, Q3 2025, Q2 2025, Q1 2025, Q4 2024, Q3 2024, Q2 2024
Across 557 measured positions in 8 quarters, the typical new or larger position finished −1.9 pts against the S&P 500 and 44% finished ahead of it. For scale, across all 501 funds with a result: −2.2 pts typical, 44% ahead.
Measured on each position this fund reported as new or larger, from the first close after the filing became public, against the S&P 500, 90 days later. Sales are not scored. History, not a forecast; it shows what the stocks did, not what the fund knew.
Total value of the 13F each quarter. It moves with prices as well as with what the fund bought or sold, so a rise is not necessarily a purchase.
| Company | Shares | Value | Weight |
|---|---|---|---|
ISHARES TR | 4.53M | $3.4B | 8.8% |
| 10.9M | $1.08B | 2.8% | |
| 1.49M | $838M | 2.2% | |
| 4.66M | $730M | 1.9% | |
Comparison uses this manager's immediately preceding 13F-HR. Puts and calls are separate lines. Share counts drive classification; reported value also moves with price.Methodology
Change in the reported value against the quarter before.
Weights are within the disclosed 13F portfolio, for the ten largest lines.
| Q1 2026 | Q2 2026 | |
|---|---|---|
| Reported value | $35.4B | $38.9B |
| Positions | 605 | 652 |
| Biggest line | — | ISHARES TR 9% |
| 3.17M |
| $538M |
| 1.4% |
| 1.34M | $499M | 1.3% |
| 1.07M | $424M | 1.1% |
| 1.77M | $422M | 1.1% |
| 2.32M | $409M | 1.1% |
| 23.4M | $371M | 1.0% |
| 775K | $356M | 0.9% |
| 895K | $356M | 0.9% |
| 1.05M | $333M | 0.9% |
| 1.25M | $329M | 0.8% |
| 2.48M | $319M | 0.8% |
| 1.17M | $298M | 0.8% |
| 3.04M | $292M | 0.8% |
| 856K | $283M | 0.7% |
| 1.71M | $282M | 0.7% |
| 291K | $281M | 0.7% |
| 6.81M | $269M | 0.7% |
| 1.85M | $261M | 0.7% |
| 2.73M | $251M | 0.6% |
| 984K | $246M | 0.6% |
| 11.3M | $244M | 0.6% |
Aersale (ASLE)
689K → 596K shares (−14%)
Silver Bow Mining (SBMT)
539K shares
Faeth Therapeutics (FTH)
144K shares
Eagle Nuclear Energy (NUCL)
2.92M → 373K shares (−87%)
Uniqure N.V. (QURE)
75K shares
Inventiva (IVA)
909K shares
Silicon Motion Technology (SIMO)
10K shares
Nurix Therapeutics (NRIX)
138K shares
Range Resources (RRC)
89K shares
Abivax (ABVX)
24K shares
Verra Mobility Corporation (VRRM)
751K shares
Alamar Biosciences (ALMR)
113K shares
Archer Aviation (ACHR)
4.73M → 636K shares (−87%)
Silvaco Group (SVCO)
753K → 214K shares (−72%)
Oculis Holding (OCS)
331K → 206K shares (−38%)
Artiva Biotherapeutics (ARTV)
100K → 274K shares (+174%)
Biontech (BNTX)
77K → 28K shares (−63%)
Argenx (ARGX)
2,811 shares
Regencell Bioscience Holdings (RGC)
416K shares
Interactive Brokers (IBKR)
29K shares
Align Technology (ALGN)
15K shares
Intercontinental Exchange (ICE)
264K → 20K shares (−92%)
Lenz Therapeutics (LENZ)
463K → 439K shares (−5%)
Coherus Oncology (CHRS)
2.25M → 1.73M shares (−23%)
Forbright (FRBT)
125K shares
